ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship
ViiV to present data for its next generation of ultra long-acting treatments
GSK`s injectable HIV drug shows promise over daily pills
ViiV Healthcare’s latest campaign to drive awareness of its HIV pre-exposure prophylaxis (PrEP) therapies enlists celebrity comedians in the familiar chatting-in-cars format.
ViiV Health announces new packaging option now available in the U.S. for Dovato
ViiV Healthcare receives approval from China’s NMPA for Vocabria
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
GSK plc (LSE/NYSE: GSK) and ViiV Healthcare will share new data on its industry-leading infectious diseases pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2023 annual meeting in Boston, US from 11-15 October 2023. Data from 47 abstracts will be presented in total, which will focus on scientific developments in a range of infectious diseases, including seasonal respiratory viruses, HIV, and chronic viral infections, affecting large patient populations.